Unknown

Dataset Information

0

Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications.


ABSTRACT:

Background

Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase (ChAT), choline transporter 1 (CHT1), vesicular acetylcholine transporter (VAChT), acetylcholinesterase (AChE) and type-2 muscarinic ACh receptors (M2AChR) to synthesize, release, degrade ACh as well as for ACh to transduce a signal. NNCS is linked to cardiac cell survival, angiogenesis and glucose metabolism. Impairment of these functions are hallmarks of diabetic heart disease (DHD). The role of the NNCS in DHD is unknown. The aim of this study was to examine the effect of diabetes on cardiac NNCS and determine if activation of cardiac NNCS is beneficial to the diabetic heart.

Methods

Ventricular samples from type-2 diabetic humans and db/db mice were used to measure the expression pattern of NNCS components (ChAT, CHT1, VAChT, AChE and M2AChR) and glucose transporter-4 (GLUT-4) by western blot analysis. To determine the function of the cardiac NNCS in the diabetic heart, a db/db mouse model with cardiac-specific overexpression of ChAT gene was generated (db/db-ChAT-tg). Animals were followed up serially and samples collected at different time points for molecular and histological analysis of cardiac NNCS components and prosurvival and proangiogenic signaling pathways.

Results

Immunoblot analysis revealed alterations in the components of cardiac NNCS and GLUT-4 in the type-2 diabetic human and db/db mouse hearts. Interestingly, the dysregulation of cardiac NNCS was followed by the downregulation of GLUT-4 in the db/db mouse heart. Db/db-ChAT-tg mice exhibited preserved cardiac and vascular function in comparison to db/db mice. The improved function was associated with increased cardiac ACh and glucose content, sustained angiogenesis and reduced fibrosis. These beneficial effects were associated with upregulation of the PI3K/Akt/HIF1? signaling pathway, and increased expression of its downstream targets-GLUT-4 and VEGF-A.

Conclusion

We provide the first evidence for dysregulation of the cardiac NNCS in DHD. Increased cardiac ACh is beneficial and a potential new therapeutic strategy to prevent or delay the development of DHD.

SUBMITTER: Saw EL 

PROVIDER: S-EPMC7898760 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications.

Saw Eng Leng EL   Pearson James T JT   Schwenke Daryl O DO   Munasinghe Pujika Emani PE   Tsuchimochi Hirotsugu H   Rawal Shruti S   Coffey Sean S   Davis Philip P   Bunton Richard R   Van Hout Isabelle I   Kai Yuko Y   Williams Michael J A MJA   Kakinuma Yoshihiko Y   Fronius Martin M   Katare Rajesh R  

Cardiovascular diabetology 20210222 1


<h4>Background</h4>Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase (ChAT), choline transporter 1 (CHT1), vesicular acetylcholine transporter (VAChT), acetylcholinesterase (AChE) and type-2 muscarinic ACh receptors (M<sub>2</sub>AChR) to synthesize, release, degrade ACh as well as for ACh to transduce a signal. NNCS is linked to cardiac c  ...[more]

Similar Datasets

| S-EPMC4367621 | biostudies-literature
| S-EPMC2518461 | biostudies-other
| S-EPMC4289578 | biostudies-literature
| S-EPMC8853531 | biostudies-literature
| S-EPMC5682336 | biostudies-literature
| S-EPMC5302024 | biostudies-literature
| S-EPMC5319473 | biostudies-literature
| S-EPMC3806714 | biostudies-literature
| S-EPMC6675555 | biostudies-literature
| S-EPMC3152549 | biostudies-literature